With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies

Lei Lei Wu

News Reporter

When Adrian Woolfson was head of R&D at Sangamo, he began contemplating starting his own company. His goal? Solve some of the key challenges plaguing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With AAV al­ter­na­tive and DNA writ­ing tech, a new hub-and-spoke start­up wants to ‘de­moc­ra­tize’ gene ther­a­pies

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies